CD8A and neoplasm: In addition, MSI-H and cytotoxic treatment may lead to an increased tumor neoantigen production, resulting from a greater rate of mutated gene, and subsequent tumor CD8-positive T-cell infiltration that, however, can be exhausted and inhibited by tumor PD-L1 expression [48].